Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry
Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry
复制标题
DOI：
10.1245/s10434-019-07453-1
复制
发表时间：
2019-08-01
影响因子：
3.7
通讯作者：
Tokuda, Yutaka
中科院分区：
文献类型：
--
作者：
Miyashita, Minoru;Niikura, Naoki;Tokuda, Yutaka
背景乳腺癌患者接受新辅助化疗（NAC）时，乳腺切除术后放疗（PMRT）的作用存在争议。我们的目的是评估与NAC和乳房切除术治疗的患者在日本乳腺癌Registry.MethodsWe招募谁接受NAC和乳房切除术的cT 1 -4 cN 0 -2 M0乳腺癌的患者放疗的有效性。我们评估了放射治疗和结果之间的关联，局部复发（LRR），无远处疾病生存（DDFS），总生存率（OS）的基础上ypN状态的多变量analysis.ResultsOf的145,530例患者，我们确定了3226谁符合纳入标准。在ypN 1患者中，放疗组和非放疗组之间的LRR、DDFS或OS无差异（分别为p=0.72、p=0.29和p=0.36）。放射治疗与无LRR生存率的改善相关（p
BackgroundThe role of postmastectomy radiotherapy (PMRT) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is controversial. We aimed to evaluate the effectiveness of radiotherapy in patients treated with NAC and mastectomy in the Japanese Breast Cancer Registry.MethodsWe enrolled patients who received NAC and mastectomy for cT1-4 cN0-2 M0 breast cancer. We evaluated the association between radiotherapy and outcomes, locoregional recurrence (LRR), distant disease-free survival (DDFS), and overall survival (OS) based on ypN status by multivariable analysis.ResultsOf the 145,530 patients, we identified 3226 who met the inclusion criteria. Among ypN1 patients, no differences were found in LRR, DDFS, or OS between groups with and without radiotherapy (p=0.72, p=0.29, and p=0.36, respectively). Radiotherapy was associated with improved LRR-free survival (p